Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05256381 · ClinicalTrials.gov registry record · Phase 2
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
A Phase 2 study, sponsored by SOTIO Biotech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 166
- Enrollment target
NCT05256381: Clinical Trial Phase 2 study, sponsored by SOTIO Biotech.
NCT05256381 is a Phase 2 study that was terminated before completion, run by SOTIO Biotech. The registered enrollment target is 166 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05256381, a Phase 2 study, was terminated before completion, sponsored by SOTIO Biotech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 166 participants
- Enrollment target
Study Summary
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
Interventions
- DRUG Pembrolizumab
- DRUG Nanrilkefusp Alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2024-11-29 |
| Phase | Phase 2 |
Why NCT05256381 stopped before completion
NCT05256381 is an interventional study that assigns participants to a tested intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% higher).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05256381 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05256381 about?
NCT05256381 is a clinical study titled "A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors". The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
What is the current status of trial NCT05256381?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 166 participants. The study started on 2022-06-21. Estimated completion is 2024-11-29.
What interventions are being tested in trial NCT05256381?
The interventions under investigation include: Pembrolizumab (DRUG), Nanrilkefusp Alfa (DRUG).
Who is sponsoring clinical trial NCT05256381?
This trial is sponsored by SOTIO Biotech, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05256381's enrollment target sits among peer trials
166 406th of 2000 higher than 1,591 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI